The antibody neutralised all known Zika strains in lab experiments, and "markedly reduced" virus levels in infected pregnant mice and their foetuses.
"This is the first antiviral that has been shown to work in pregnancy to protect developing foetuses from Zika virus," said study co-author Michael Diamond of the Washington University School of Medicine.
"This is proof of principle that Zika virus during pregnancy is treatable and that we already have a human antibody that treats it, at least in mice."
In most people it is benign with mild or no symptoms. But in an outbreak that started in 2015, it has been linked to microcephaly in foetuses -- a condition which restricts head growth and causes brain damage.
More 2,300 babies, mainly in Brazil, have been born with microcephaly or other Zika-related central nervous system malformations since last year, according to the World Health Organization (WHO).
There is no cure or vaccine.
Diamond and a team trawled through antibody samples from people who had recovered from a Zika infection.
Antibodies are the footsoldiers in the body's defences.
They are Y-shaped proteins produced by the immune system in response to the presence of so-called antigens -- disease-causing pathogens.
Each type of antibody binds to a specific antigen, then inactivates it directly or tags it for destruction by other immune cells.
The researchers gave ZIKV-117 to pregnant mice who had been injected with Zika, and found their placentas remained normal and healthy compared to non-treated mice.
"Almost all foetuses were protected against infection and disease," Diamond told AFP.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
